Stock KRON KRONOS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Kronos Bio, Inc.

Equities

KRON

US50107A1043

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-30 EDT 		5-day change 1st Jan Change
1.03 USD +3.00% Intraday chart for Kronos Bio, Inc. +8.42% -17.60%
03-21 Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M MT
03-21 Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M
MT
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
GL
Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Kronos Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
GL
Kronos Bio, Inc. Announces to Assess KB-0742 At Planned New Dose Schedule in Ongoing Phase 1/2 Study
CI
Kronos Bio Plans to Reduction in Force
CI
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
GL
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
GL
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
AQ
Kronos Bio Announces Management Shakeup, 3 Top Managers to Step Down in February
MT
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
GL
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
AQ
Kronos Bio, Inc. Announces Executive Changes
CI
Investors got more clues that rate cuts are imminent
Our Logo
Piper Sandler Trims Price Target on Kronos Bio to $6 From $7, Keeps Overweight Rating
MT
HC Wainwright Adjusts Price Target on Kronos Bio to $2.50 From $9, Keeps Buy Rating
MT
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
GL
Kronos Bio, Inc. Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KRON Stock
  4. News Kronos Bio, Inc.